Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OK › Grove › NPI 1467473579
Hospital

Integris Grove Hospital

Integris Grove Hospital was paid $5.80M by Medicaid between Jan 2018 and Dec 2024, across 67 billing codes. Its largest line is 99283, emergency room visit (moderate) — 54% of everything it billed.

33Billing provider infoINTEGRIS GROVE HOSPITAL
GROVE, OK 74344
33aNPI1467473579assigned 07/22/2006
28Total paid$5.80M
24GClaims68,626
24DCodes billed67
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Oklahoma

Rank by total paid#27 of 75
Median peer was paid$3.66M
This provider vs. median1.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WALLACE, DONNA controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$100K$200K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20186,619$691K
20196,436$594K
20205,637$482K
202110,374$815K
202215,563$1.23M
202316,297$1.31M
2024incomplete7,700$686K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 54% 19,403 19,181 $3.15M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 16% 4,184 4,133 $954K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 9.9% 1,884 1,852 $577K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 3.0% 1,383 1,352 $173K
69436 Tympanostomy (requiring insertion of ventilating tube), general anesthesia 2.2% 141 141 $125K
99282 Emergency department visit for the evaluation and management, low to moderate severity 1.2% 778 772 $72K
36415 Collection of venous blood by venipuncture <1% 6,017 5,708 $57K
80053 Comprehensive metabolic panel <1% 3,352 3,211 $55K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 3,478 3,196 $48K
71045 Radiologic examination, chest; single view <1% 2,708 2,647 $47K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 326 323 $43K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 1,154 1,148 $42K
55 more codes
87400 <1% 1,368 $39K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 463 $35K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 590 $31K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 223 $30K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,798 $25K
96361 Intravenous infusion, hydration; each additional hour <1% 629 $25K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 128 $22K
83690 <1% 672 $18K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 897 $18K
96375 Therapeutic injection; each additional sequential IV push <1% 197 $17K
70450 Computed tomography, head or brain; without contrast material <1% 277 $15K
84484 <1% 976 $15K
83880 <1% 379 $14K
81003 <1% 1,641 $14K
87430 <1% 841 $14K
85610 <1% 703 $14K
85027 <1% 1,454 $13K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 150 $13K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 1,256 $10K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 190 $9K
87070 <1% 746 $7K
J7030 Infusion, normal saline solution , 1000 cc <1% 1,776 $7K
81001 <1% 2,303 $7K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 60 $6K
80048 Basic metabolic panel (calcium, ionized) <1% 747 $5K
80179 <1% 318 $5K
80143 <1% 318 $5K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 37 $5K
81025 <1% 544 $4K
83655 <1% 344 $4K
73630 <1% 211 $4K
73110 <1% 106 $3K
87807 <1% 194 $2K
71046 Radiologic examination, chest; 2 views <1% 92 $2K
87420 <1% 99 $1K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 27 $1K
88304 <1% 27 $1K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 14 $1K
85018 <1% 419 $819.01
73562 <1% 48 $783.43
81002 <1% 125 $372.09
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 32 $364.87
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 188 $268.64
85730 <1% 39 $187.25
87040 <1% 12 $184.04
87210 <1% 28 $137.11
86850 <1% 12 $104.28
83036 Hemoglobin; glycosylated (A1C) <1% 12 $91.68
85379 <1% 13 $81.45
88720 <1% 16 $71.52
86900 <1% 12 $31.92
86901 <1% 12 $31.92
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 30 $2.41
J1200 Injection, diphenhydramine hcl, up to 50 mg 0% 13 $0.00
J1100 Injection, dexamethasone sodium phosphate, 1 mg 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWALLACE, DONNA (VP FINANCE)
Same official

Other billing entities under WALLACE, DONNA

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.